13F HOLDINGS REPORT
Sanofi
Quarter ended Q4 2024 · Filed February 14, 2025 · Accession 0000950123-25-002465
Total Value
$174.4M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | MGTX | 12,197,737 | $74.3M | 42.60% |
| 2 | Novavax | NVAX | 6,880,481 | $55.3M | 31.73% |
| 3 | Inhibrx Biosciences, Inc. | INBX | 1,157,926 | $17.8M | 10.23% |
| 4 | AnaptysBio | ANABV | 821,917 | $10.9M | 6.24% |
| 5 | IGM Biosciences | 449585108 | 1,438,975 | $8.8M | 5.04% |
| 6 | Eledon | ELDN | 814,980 | $3.4M | 1.93% |
| 7 | LAVA Therapeutics N.V. | N51517105 | 1,919,455 | $1.8M | 1.05% |
| 8 | Inozyme, Inc | 45790W108 | 443,255 | $1.2M | 0.70% |
| 9 | Q32 Bio Inc. | QTTB | 244,083 | $839,646 | 0.48% |